With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb

“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.

• Source: Shutterstock

Brent Saunders didn’t use his first quarterly earnings briefing since returning to Bausch + Lomb Corp.’s helm to list potential targets identified for change and pledge to later provide details on a plan.

Saunders delivered his plan to change B+L in his opening remarks during the Canadian firm’s discussion of its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

People On The Move: Appointments at Opella, NèreS, Haleon

 
• By 

A round-up of the latest consumer health industry moves: Opella names France head; NèreS elects president; Haleon has new Saudi GM.

US Consumer Health Executive News: CHPA Regulatory SVP, Kenvue CFO, PLT Sales Head

 

Former FDA OTC division director joins CHPA; PLT Health names global sales chief; and Kenvue loses CFO to Mattel, hires replacement from Kellanova.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By 

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

More from HBW Insight

Venture Life Focuses On CHC As It Offloads CDMO

 
• By 

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By 

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn